Neuronetics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64131A1051
USD
1.55
-2.17 (-58.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Neuronetics, Inc. stock-summary
stock-summary
Neuronetics, Inc.
Pharmaceuticals & Biotechnology
Neuronetics, Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States.
Company Coordinates stock-summary
Company Details
3222 Phoenixville Pike , MALVERN PA : 19355-9615
stock-summary
Tel: 1 610 640420261 410 6272087
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 21 Schemes (10.28%)

Foreign Institutions

Held by 34 Foreign Institutions (4.49%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Brian Farley
Independent Non-Executive Chairman of the Board
Mr. Keith Sullivan
President, Chief Executive Officer, Director
Mr. John Bakewell
Director
Ms. Sheryl Conley
Independent Director
Dr. Wilfred Jaeger
Independent Director
Mr. Glenn Muir
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
37 Million
(Quarterly Results - Sep 2025)
Net Profit:
-9 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 132 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.34

stock-summary
Return on Equity

-161.16%

stock-summary
Price to Book

4.81